Twist Bioscience Corporation

Small-cap stocks have benefited from a range of tailwinds this year.

During the third quarter of 2026, the Polen 5Perspectives Growth Opportunities Composite Portfolio returned -6.2% net of fees compared to the 0.5% return of the Russell 3000 Growth Index. The top contributors to relative performance in the period were Twist Bioscience, CrowdStrike and Micron Technology (underweight). The most significant detractors from the Portfolio's relative performance in the quarter were Argan, Microsoft (underweight), and Bloom Energy.

The top contributors to the Portfolio's relative performance in the quarter were Twist Bioscience, RingCentral, and Five9. The most significant detractors from the Portfolio's relative performance in the quarter were Terawulf, nLight, and Brookdale Senior Living. The salient changes to positioning this quarter included our increased exposure to Health Care and decreased exposure to Industrials.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST): UNITED STATES DISTRICT COURT DISTRICT OF DELAWARE IN RE TWIST BIOSCIENCE CORPORATION DERIVATIVE LITIGATION Lead Case No. 1:23-cv-01048-MN SUMMARY NOTICE OF PROPOSED SETTLEMENT OF DERIVATIVE ACTION TO: ALL CURRENT RECORD HOLDERS AND BENEFICIAL OWNERS OF TWIST BIOSCIENCE CORPORATION (“TWIST” OR THE “COMPANY”) COMMON STOCK AS OF OCTOBER 15, 2026 (THE “RECORD DATE”). IF YOU WERE A RECORD OR BENEFICIAL OWNER O.

We remain encouraged by the operational performance of the Micro cap companies held in portfolios. TWST shares surged as a strong fiscal 3Q highlighted accelerating demand across several of the company's end markets. TKNO management responded to the stronger first half by substantially raising its full-year revenue outlook.

The portfolio's outperformance was primarily driven by our holdings in the Health Care sector, which delivered strong returns for the quarter on company-specific catalysts. Information Technology holdings and underweight to the Energy sector detracted from returns. For the year-to-date period, the Fund returned 5.80% (net of fees), outperforming the Russell Midcap Growth Index's 1.01%.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched Twist MRD Express, custom panels manufactured at scale with a rapid turnaround time starting within one day. Twist MRD Express custom panels enable cancer researchers to investigate tumor-associated genomic variants and support studies in oncology research, biomarker discovery and assay development. Molecular residual disease (MRD) is the presence.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its antibody production and characterization portfolio with the launch of Twist Express Screening Antibodies, a high-throughput cell-free offering that delivers purified full-length IgG with SPR binding characterization. Twist Express Screening Antibodies accelerate the path from sequence to purified antibody and binding characterization across br.

After delivering results well above expectations, TWST management significantly raised its outlook and projected triple-digit growth in orders. During the quarter, LIFE shares performed well following a strong earnings beat. During the quarter, several key approvals and coverage expansions supported product growth for GH.

The portfolio generated a negative absolute return but outpaced the Russell Midcap Growth Index. During the quarter, we initiated new positions in Manhattan Associates, Okta and Clean Harbors. We ended our investment campaign in Monolithic Power Systems, FTAI Aviation and Ionis Pharmaceuticals during the quarter.

Forte Biosciences Inc., Twist Bioscience Corp., and Adaptive Biotechnologies Corp., were among the top contributors to performance. Cardinal Infrastructure Group, Inc., RBC Bearings Incorporated, and VSE Corporation were among the top detractors from performance. VSE Corporation shares detracted from performance during the quarter despite strong revenue growth, record profitability, and an improved full-year outlook.

Both of these ETFs look the part, but only one is truly the better buy for investors.

Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report)'s stock price dropped 7.4% on Friday. The stock traded as low as $134.83 and last traded at $133.8060. 180,478 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 1,711,585 shares. The stock had previously closed at $144.49. Analyst Ratings Changes

During Q3 2026, the Polen 5Perspectives Small-Mid Growth Composite Portfolio returned -12.5% (net of fees) compared to the -10.4% return of the Russell 2500 Growth Index. The top contributors to the Portfolio's relative performance in the quarter were Twist Bioscience, Twilio, and Embraer. The most significant detractors from the Portfolio's relative performance in the quarter were nLight, Terawulf, and BWX Technologies.

.Danaher (DHR), one of the world's largest providers of medical diagnostics and laboratory equipment, recently announced plans to launch its first AI-powered autonomous laboratory, scheduled to operate at commercial scale in early 2027. While market trading barely moved the stock on the announcement date, the news marks a quiet turning point for life science automation.

Forget the "Magnificent Seven" in favor of the "Tremendous Three"?

Quantum-Si (NASDAQ: QSI - Get Free Report) and Twist Bioscience (NASDAQ: TWST - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Valuation and Earnings This table compares Quantum-Si and Twist

Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report)'s share price dropped 9.7% during mid-day trading on Tuesday after an insider sold shares in the company. The company traded as low as $186.61 and last traded at $185.0970. 1,748,314 shares traded hands during trading, an increase of 8% from the average daily volume of 1,618,778 shares.

Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).

Twist Bioscience Corp. (NASDAQ:TWST) shares are trading lower Friday, pulling back after touching a fresh 52-week high near $192 earlier in the session. Here's what you should know.